Outcomes in COVID-19 cyproheptadine studies

All studies   Mortality   Hospitalization   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -30% 2 136 Improvement, Studies, Patients Relative Risk Mortality -30% 2 136 Hospitalization -49% 1 40 RCTs -30% 2 136 RCT mortality -30% 2 136 Late -30% 2 136 Cyproheptadine for COVID-19 c19early.org November 2025 Favorscyproheptadine Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] death 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Boniatti (RCT) -11% 1.11 [0.48-2.57] death 7/19 7/21 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Late treatment -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk All studies -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk 2 cyproheptadine COVID-19 studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Effect extraction pre-specified(most serious outcome) Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Boniatti (RCT) -11% 1.11 [0.48-2.57] 7/19 7/21 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Late treatment -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk All studies -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk 2 cyproheptadine COVID-19 mortality results c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Boniatti (RCT) -49% 1.49 [0.94-2.35] hosp. time 19 (n) 21 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.091 Late treatment -49% 1.49 [0.94-2.35] 19 (n) 21 (n) 49% higher risk All studies -49% 1.49 [0.94-2.35] 19 (n) 21 (n) 49% higher risk 1 cyproheptadine COVID-19 hospitalization result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.091 Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] death 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Boniatti (RCT) -11% 1.11 [0.48-2.57] death 7/19 7/21 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Late treatment -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk All studies -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk 2 cyproheptadine COVID-19 serious outcomes c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Effect extraction pre-specified(most serious outcome) Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -122% 2.22 [1.32-3.85] no recov. 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0036 Late treatment -122% 2.22 [1.32-3.85] 35 (n) 61 (n) 122% higher risk All studies -122% 2.22 [1.32-3.85] 35 (n) 61 (n) 122% higher risk 1 cyproheptadine COVID-19 recovery result c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0036 Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] death 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Boniatti (RCT) -11% 1.11 [0.48-2.57] death 7/19 7/21 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Late treatment -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk All studies -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk 2 cyproheptadine COVID-19 Randomized Controlled Trials c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Effect extraction pre-specified(most serious outcome) Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Boniatti (RCT) -11% 1.11 [0.48-2.57] 7/19 7/21 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Late treatment -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk All studies -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk 2 cyproheptadine COVID-19 RCT mortality results c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] death 35 (n) 61 (n) Improvement, RR [CI] Treatment Control Boniatti (RCT) -11% 1.11 [0.48-2.57] death 7/19 7/21 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Late treatment -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk All studies -30% 1.30 [0.73-2.33] 7/54 7/82 30% higher risk 2 cyproheptadine COVID-19 peer reviewed studies c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.38 Effect extraction pre-specified(most serious outcome) Favors cyproheptadine Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ I-SPY COVID Auld (RCT) -51% 1.51 [0.67-3.37] death 35 (n) 61 (n) Improvement, RR [CI] Treatment Control I-SPY COVID Auld (RCT) -206% 3.06 [1.50-6.24] death/int. 35 (n) 61 (n) I-SPY COVID Auld (RCT) -122% 2.22 [1.32-3.85] no recov. 35 (n) 61 (n) Boniatti (RCT) -11% 1.11 [0.48-2.57] death 7/19 7/21 Boniatti (RCT) -49% 1.49 [0.94-2.35] hosp. time 19 (n) 21 (n) Cyproheptadine COVID-19 outcomes c19early.org November 2025 Favors cyproheptadine Favors control